Cargando…
Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer
BACKGROUND: Pancreatic cancer is a major cause of cancer-related death, with a 5-year overall survival rate being below 5%. The main causes of poor prognosis in pancreatic cancer include easy metastasis, high recurrence rate, and robust drug resistance. Gemcitabine is a first-line drug for patients...
Autores principales: | Wei, Li, Wen, Jing-Yun, Chen, Jie, Ma, Xiao-Kun, Wu, Dong-Hao, Chen, Zhan-Hong, Huang, Jiang-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785518/ https://www.ncbi.nlm.nih.gov/pubmed/31602160 http://dx.doi.org/10.3748/wjg.v25.i37.5590 |
Ejemplares similares
-
Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model
por: Yehya, Ashwaq Hamid Salem, et al.
Publicado: (2022) -
Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020) -
MicroRNA-30c inhibits pancreatic cancer cell proliferation by targeting twinfilin 1 and indicates a poor prognosis
por: Sun, Lu-Lu, et al.
Publicado: (2019) -
Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth
por: Wu, Meng-Na, et al.
Publicado: (2021) -
Low expression of CDK5RAP3 and DDRGK1 indicates a poor prognosis in patients with gastric cancer
por: Lin, Jian-Xian, et al.
Publicado: (2018)